(VIANEWS) – Shares of PCI BIOTECH HOLD (Oslo Børs All-share Index_GI: PCIB.OL) fell by a staggering 26.56% in 10 sessions from $3.2 to $2.35 at 13:49 EST on Monday, after five sequential sessions in a row of losses. Oslo Børs All-share Index_GI is falling 0.89% to $1,365.78, after successive sessions in a row of losses.
PCI BIOTECH HOLD’s last close was $2.45, 62.38% under its 52-week high of $6.50.
About PCI BIOTECH HOLD
PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.
Earnings Per Share
As for profitability, PCI BIOTECH HOLD has a trailing twelve months EPS of $-1.937.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -73.59%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
PCI BIOTECH HOLD’s EBITDA is 0.99.
More news about PCI BIOTECH HOLD (PCIB.OL).
